Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced a positive safety review for the ongoing Phase 1b SP-03-B101 trial of Sapu003. The independent Safety Review Committee completed its review of the initial three-patient safety cohort and found no dose-limiting toxicities, recommending advancement to the next planned dose level. This milestone marks a significant step in the clinical development of the intravenous everolimus formulation.
The company also revealed plans to expand the study into Europe by adding additional clinical sites. This expansion aims to broaden patient access and support enrollment, potentially accelerating the trial's progress. The positive safety review follows the publication of peer-reviewed research detailing the scientific foundation of the Deciparticle™ nanomedicine platform and the Sapu003 formulation. According to Oncotelic, the publication underscores the platform's scalable manufacturing capabilities, stability, and preclinical antitumor activity, reinforcing the ongoing clinical development program.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company's pipeline benefits from the expertise of CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, Oncotelic licenses and co-develops drug candidates through joint ventures, including a 45% stake in GMP Bio. The company also develops PDAOAI, a proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing, which underpins its partnership with SAPU Bio and TechForce Robotics.
The implications of this announcement are significant for patients and the oncology field. Sapu003, based on the Deciparticle platform, aims to improve the delivery and efficacy of everolimus, a drug used in various cancers. A positive safety profile and progression to higher doses could lead to more effective treatments with fewer side effects. The planned European expansion indicates a global strategy to gather diverse patient data, which may strengthen the trial's outcomes and regulatory submissions. For investors, the milestone reflects progress in Oncotelic's pipeline, potentially enhancing the company's valuation and partnership opportunities.
For more information, visit www.oncotelic.com. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
